Cargando…

A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients

BACKGROUND: The hemodialysis (HD) population has been a vulnerable group during the coronavirus disease 2019 (COVID-19) pandemic. Advanced chronic kidney disease with uremia is associated with weaker immune response to infections and an attenuated response to vaccines. The aim of this study was to s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melin, Jan, Svensson, Maria K, Albinsson, Bo, Winqvist, Ola, Pauksens, Karlis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Academia 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602199/ https://www.ncbi.nlm.nih.gov/pubmed/36337280 http://dx.doi.org/10.48101/ujms.v127.8959

Ejemplares similares

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
por: Melin, Jan, et al.
Publicado: (2021)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2022)

Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection
por: Niesen, Michiel J M, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
por: Bensouna, Ilias, et al.
Publicado: (2022)

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
por: Grassi, Tiziana, et al.
Publicado: (2022)

Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers
por: Tanaka, Hidenori, et al.
Publicado: (2023)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients
por: Housset, Pierre, et al.
Publicado: (2022)

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
por: Saresella, Marina, et al.
Publicado: (2022)

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Henig, Israel, et al.
Publicado: (2023)

Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
por: Athanasiou, Nikolaos K., et al.
Publicado: (2023)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
por: Saiag, Esther, et al.
Publicado: (2022)

Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer
por: Debie, Yana, et al.
Publicado: (2022)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
por: Herzberg, Jonas, et al.
Publicado: (2022)

Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
por: Tamura, Miku, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients
por: Ruggeri, Enzo Maria, et al.
Publicado: (2022)

Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2022)

A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
por: Tomiyama, Takahiro, et al.
Publicado: (2023)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
por: Yau, Kevin, et al.
Publicado: (2021)

A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
por: Martora, Fabrizio, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
por: Yanay, Noa Berar, et al.
Publicado: (2021)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
por: Re, Daniel, et al.
Publicado: (2022)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
por: Hussein, Khetam, et al.
Publicado: (2022)

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents
por: Mu, Xiaofeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e78m3tf330m321349mfm0efd2d